

## Republic of the Philippines Department of Health FOOD AND DRUG ADMINISTRATION



FDA ADVISORY Nd: 2016-127 1 1 NOV 2016

TO:

ALL HEALTHCARE PROFESSIONALS AND THE

**GENERAL PUBLIC** 

**SUBJECT:** 

Public Health Warning Against the Use of the Unregistered

<u>Drug Product "Dydrogesterone (Duphaston) 10 mg Film</u> Coated Tablet" manufactured by Highnoon Laboratories,

Ltd. - 17.5 K.M. Multan Road, Lahore

The Food and Drug Administration (FDA) advises the public against the use of the unregistered drug product Dydrogesterone (Duphaston) 10 mg Film Coated Tablet:



## **Dydrogesterone 10 mg Film Coated Tablets**

Manufactured by: Highnoon Laboratories Ltd. - 17.5 K.M. Multa Road, Lahore

For: Abbott Laboratories (Pakistan) Ltd. - Landhi, Karachi, Pakistan

Under License from: Abbott Healthcare Products B.V., Weesp, Holland

Figure 1. Secondary packaging of the unregistered Dydrogesterone (Duphaston) 10 mg Tablet






Figure 2. Secondary packaging of the registered Dydrogesterone (Duphaston) 10 mg Tablet (Registration Number: DRP-221)



Figure 3. Comparison of the blister packs of unregistered and registered Dydrogesterone (Duphaston) 10 mg Tablet

Please be informed that the registered Dydrogesterone (Duphaston) 10 mg Film Coated Tablets has Registration Number DRP-221 and imported by Abbott Products (Philippines) Inc., Marketing Authorization Holder (MAH).

All healthcare professionals and the general public are hereby warned to be vigilant of the abovementioned unregistered drug product. This product poses potential danger or injury to the consuming public and the importation, selling or offering for sale of such is in direct violation of Republic Act No. 9711 or the Food and Drug Administration Act of 2009.

In the interest of protecting public health and safety, the Officers of the Field Regulatory Operations Office (FROO) are hereby mandated to exercise their regulatory function pursuant to Section 14 of Republic Act. No. 9711.

All establishments and outlets are hereby warned against selling and/or dispensing the unregistered product identified above. Anyone found selling the said product will be penalized.

Likewise, all local government units and law enforcement agencies are requested to ensure that this unregistered product is not sold or offered for sale in their localities or area of jurisdiction.

Consumers are advised to purchase their medications only from FDA-licensed establishments. In addition to inspection of establishments, product evaluation, registration, and testing are measures that the government undertakes to ensure the quality, safety, and efficacy of health products. Please look for the FDA Registration number on the product label. Be reminded that drug products registered with FDA Philippines bear in their labels information in English and/or in Filipino for all consumers to understand.

For more information and inquiries, please e-mail us at <a href="mailto:info@fda.gov.ph">info@fda.gov.ph</a>. To report continuous sale or distribution of unregistered health products, kindly e-mail us via <a href="mailto:report@fda.gov.ph">report@fda.gov.ph</a> or you may call telephone number (02)807-8275. For any suspected adverse drug reaction (ADR), report immediately to FDA through this link: <a href="mailto:www.fda.gov.ph/adr-report-new">www.fda.gov.ph/adr-report-new</a> and fill out all the required fields.

Dissemination of the information to all concerned is requested.

NELA CHARADE G. PUNO, RPh

Director General

DTN:20160822135658